Cytomegalovirus (CMV) infection is the most important congenital viral infection. Intravenous (i.v.) Ganciclovir (GCV) improved outcome in term infants with symptomatic congenital CMV infection. We present data on oral valganciclovir (VGCV) in an extremely low birth weight infant.
Introduction
Cytomegalovirus (CMV) infection is the most important congenital viral infection. Most infants with symptomatic infection will develop severe sequelae later in life such as sensorineural hearing loss and mental retardation.
Ganciclovir (GCV) was evaluated in phase II and randomized phase III studies to prevent progression of the disease. 1, 2 Nevertheless, antiviral treatment is not yet generally accepted because of prolonged need of intravenous (iv) access for at least 6 weeks and significant side effects. 3 
Case
An 18-year-old mother was admitted to the hospital because of suspected pre-eclampsia and intrauterine growth retardation. The male preterm infant was delivered 1 day after admission at 28 weeks of gestation because of abnormal fetal perfusion with severe intrauterine growth retardation. The APGAR-score at 1, 5 and 10 min was 8, 8 and 9 and the umbilical artery pH was 7.33. The birth weight was 430 g (below third percentile level), height 26 cm (below third percentile level) and head circumference 21 cm (below third percentile level).
Because of respiratory distress surfactant was administered and breathing was supported by nasal continuous positive airway pressure.
Laboratory values showed thrombocytopenia, neutropenia and cholestasis. Serology revealed a positive CMV IgM (CMV-IgM-ELA Test PKS, Medac, Hamburg, Germany) in maternal serum 3 days after delivery. At day 4 determination of the CMV virus load (artus CMV LC PCR Kit, Qiagen, Hilden, Germany) in the infant plasma and urine samples showed 18 990 and 42 205 copies ml À1 (Table 1) . Treatment with iv GCV (5 mg kg À1 daily two times) was started at day 4 of life and was continued for 35 days. Thrombocytopenia and hepatitis with elevated liver enzymes and direct hyperbilirubinemia persisted during iv GCV treatment. Plasma GCV levels were 3.54 ng ml À1 (peak) and 0.62 ng ml
À1
(trough) on day 25 of the i.v. GCV treatment. Three days after discontinuation of i.v. GCV, the plasma and urine viral load rose to 91 610 and 873 500 copies ml À1 . Therefore, antiviral therapy was continued with oral administration of valganciclovir (VGCV) (5 mg kg À1 daily two times) for further 6 weeks. The VGCV liquid suspension was compounded from valganciclovir hydrochloride tablets (Valcyte, Roche Pharmaceuticals, Nutley, New Jersey, USA) with a final concentration of 20 mg ml À1 and 1 mg ml À1 potassium sorbate.
At day 65 of life, that is, at day 17 of oral VGCV treatment, plasma GCV levels were 1.68 ng ml À1 (peak) and 0.92 ng ml À1 (trough) and plasma and urine viral load decreased to <1000 and 3285 copies ml À1 (Table 1) . Thrombocytopenia and laboratory signs of hepatitis (elevated liver enzymes and direct hyperbilirubinemia) resolved during oral therapy (Table 1) .
At discharge and at 6 months of corrected age brain stemevoked audiometry was normal. Neurodevelopmental assessment by Griffith's test at an corrected age of 3 and 6 months showed a mild neurodevelopmental delay of 4 weeks.
Discussion
Intravenous GCV treatment for symptomatic congenital CMV infection has been shown to improve hearing and developmental outcome in this patient group. 1 Yet this treatment is associated with the potential side effects of long-term use of intravenous lines (for example, catheter-related bloodstream infections). Oral administration of GCV is not an alternative because of its low bio-availability. Since a few years, oral administration of VGCV is widely used in prophylaxis and treatment of CMV infection in adult and pediatric transplant patients. During absorption VCGV is converted into GCV, so that VCGV plasma concentrations are undetectable. Recently, a pharmacokinetic study has shown that intravenous GCV (6 mg kg À1 ) and oral VGCV (16 mg kg À1 ) result in similar plasma concentrations of GCV in neonates with symptomatic CMV infection. 4 Sufficient plasma levels and suppression of plasma and urine virus load have also been described in single case studies in term neonates with symptomatic CMV infection. 5, 6 Similar to a recent report by Galli et al., 7 who reported partial suppression of viruria at peak plasma levels of 0.42 and 3.1 mg ml À1 in newborn infants treated with VGCV, we observed partial suppression of viremia at plasma trough levels of 0.61 to 0.92 mg ml À1 and plasma peak levels of 1.68 to 2.00 mg ml À1 (Table 1) . In our case, we describe an extremely low birth weight infant (that is, an infant with a birth weight of less than 1000 g) with symptomatic congenital CMV with associated hepatitis and thrombocytopenia, which resolved while being treated with oral VGCV. After the diagnosis of symptomatic congenital CMV infection, standard therapy with i.v. GCV was initiated for 6 weeks. However, despite iv GCV treatment for 6 weeks, viral replication was not successful suppressed and clinical symptoms (for example, thrombocytopenia and hepatitis) persisted. Therefore, antiviral therapy was continued with oral VGCV. Oral VGCV was chosen because the infant was on full enteral nutrition and did not require iv access despite weighing still less than 1000 g. Serial measurements of GCV peak and trough levels confirmed sufficient bio-availability of orally administered VGCV in this extremely low birth weight infant, side effects of oral VGCV were not observed.
In conclusion, oral treatment with VGCV in an extremely low birth weight infant with congenital CMV infection resulted in adequate GCV plasma levels, reduced effectively the CMV viral load and was well tolerated without apparent adverse effects. Studies to evaluate pharmacokinetics, efficacy and safety of oral VGCV therapy in neonates and especially preterm infants with congenital CMV infection are necessary. 
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